Vmn1r86 inhibitors are chemical compounds that specifically target and inhibit the activity of the Vmn1r86 protein, which belongs to the vomeronasal receptor family. Vmn1r86 is a type of G-protein coupled receptor (GPCR) that plays a role in chemical signal transduction. These receptors are primarily involved in detecting pheromones and other semiochemicals, which are substances that elicit specific behavioral or physiological responses in organisms. Inhibitors of Vmn1r86 are designed to interfere with the receptor's ability to bind to its natural ligands, preventing downstream signaling pathways from being activated. This type of inhibition can help researchers investigate the biological functions of Vmn1r86 by understanding how blocking its activity impacts the organism's response to environmental signals.
The study of Vmn1r86 inhibitors is valuable in exploring the broader role of vomeronasal receptors in sensory perception, especially in species that rely heavily on chemical communication. These inhibitors allow for the dissection of complex signaling networks and offer insights into how specific receptor-ligand interactions influence behavior and physiological responses. By inhibiting Vmn1r86, researchers can also examine its role in modulating neural circuits and sensory processing pathways, contributing to a deeper understanding of olfactory systems. Additionally, Vmn1r86 inhibitors can be useful tools in chemical biology to study protein-ligand interactions, providing valuable information for identifying other ligands or molecular partners involved in vomeronasal receptor signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic receptor antagonist, potentially modulating GPCR signaling and indirectly affecting Vmn1r86. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Histamine H2 receptor antagonist, may alter GPCR-mediated processes, potentially impacting Vmn1r86. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Serotonin receptor antagonist, could affect GPCR signaling pathways, influencing Vmn1r86 indirectly. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, potentially affecting noradrenergic signaling related to Vmn1r86. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor antagonist, could modulate GPCR pathways, potentially influencing Vmn1r86 activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker, may affect calcium signaling pathways, potentially related to Vmn1r86. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Inhibits Gi/o proteins, potentially affecting GPCR-mediated signaling pathways involved with Vmn1r86. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Sodium channel blocker, might indirectly influence signaling mechanisms relevant to Vmn1r86. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor, could affect downstream signaling pathways that might impact Vmn1r86 function. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Dopamine receptor antagonist, might influence GPCR-mediated signaling pathways related to Vmn1r86. | ||||||